Modality
Gene Editing
MOA
Anti-Tau
Target
WEE1
Pathway
T-cell
CeliacCKD
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Apr 2031
Phase 1Current
NCT04001486
2,898 pts·Celiac
2025-12→2031-04·Recruiting
2,898 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-165.0y awayPh2 Data· Celiac
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2031-04-16 · 5.0y away
Celiac
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04001486 | Phase 1/2 | Celiac | Recruiting | 2898 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |